* The 8 patients withdrew consent after being randomised (SIRT n=2, sorafenib n=6). According to French law, the data of these patients cannot be used in the analysis.

† Lung shunting (n=14), worsening disease (n=4), arterio-portal shunt (n=2), extra-hepatic disease (n=1), extra-hepatic uptake on MAA (n=1), no tumour uptake on MAA (n=1), technical reasons (n=3: no selective catheterisation n=2, iliac pseudo aneurism n=1).

‡ Pulmonary embolism (n=1), worsening disease (n=8), early death (n=2), technical reasons (n=5: arterio-portal shunt n=1, hepatic arterial thrombosis n=1, extra-hepatic uptake on MAA n=1, no tumour uptake on MAA n=1 and lung shunting n=1).

§ Additional patients have also not meet inclusion criteria (n=2) and received sorafenib instead of SIRT (n=1).

Vilgrain V et al.  Lancet Oncol 2017; 18: 1624–36.

Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage